Pulse Biosciences, Inc., a company leveraging its novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation energy, announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026.
Health Technology Insights: CareTrust Acquires $142 Million Mid-Atlantic Nursing Portfolio
“We are delighted to welcome Maria to our Board of Directors,” said Pulse Biosciences’ Co-Chairman of the Board Robert W. Duggan. “She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional markets with our patient-first mission.”
Health Technology Insights: Incyte Reports Positive Topline Results for Tafasitamab in DLBCL
Mrs. Sainz brings over three decades of experience in healthcare technology, including 18 years in CEO roles leading publicly traded companies and venture-backed startups. Currently, she serves as President and CEO of Hyperfine, Inc., a medical technology company with a commercial stage portable brain MRI system. Previously, she served as President and CEO of Aegea Medical, a VC-backed women’s health company, President and CEO of CardioKinetix Inc., a VC-backed company in interventional heart failure therapy, and as President and CEO of Concentric Medical, a VC-backed stroke thrombectomy company. Prior to her CEO roles, Mrs. Sainz served in various leadership capacities at Guidant Corporation and Boston Scientific Corporation, including as Strategic Advisor to the COO, President of the Cardiac Surgery Division, Vice President of Global Marketing for Vascular Intervention, and Vice President for CRM and Cardiac Surgery in EMEA. In addition, she has served on the board of numerous companies including Shockwave Medical Spectranetics Corp Avanos Medical Orthofix Medical Inc , Hyperfine and several private medical device companies. Mrs. Sainz holds a Master of English from the Complutense University of Madrid and a Master of International Management from Thunderbird School of Global Management.
“I am honored to join Pulse’s Board of Directors at this pivotal stage, as its first three programs advance through key clinical, regulatory, and commercial milestones,” said Maria Sainz. “Pulse is very well positioned and Nanosecond PFA technology is exceptionally differentiated and has critical applications in large clinical markets. I look forward to working with the leadership team and contributing strategic guidance as the Company expands its clinical evidence, accelerates commercialization, and drives short, intermediate, and long-term value creation.”
Health Technology Insights: Natera Launches 21-Gene Fetal Focus Single-Gene NIPT
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
